Endothelial and microvascular function in liver cirrhosis: an old concept that needs re-evaluation?

Ioanna Papagiouvanni a, Pantelis Sarafidis b, Marieta P. Theodorakopoulou b, Emmanouil Sinakos a, Ioannis Goulis a
Hippokration Hospital, Aristotle University of Thessaloniki, Greece

Abstract
Liver cirrhosis is characterized by significant circulatory dysregulation, related to an imbalance among several vasodilating agents, mainly nitric oxide. In contrast to portal vein and macrovascular hemodynamic alterations, which have been rather well described, the peripheral microcirculatory and endothelial structure and function in this population are less well studied. Endothelial dysfunction is characterized by an imbalance between endothelium-derived relaxing and contracting factors. A number of methods have been used to assess endothelial and microvascular function in human studies. Venous occlusion plethysmography was used for many years as the gold standard for evaluating endothelial function, but flow-mediated dilatation (FMD) of the forearm is currently the most frequently used method. In patients with cirrhosis, the few existing studies have mainly used FMD, but the relevant results are largely contradictory. In recent years, several noninvasive and easily applicable methods, such as near-infrared spectroscopy, laser speckle contrast imaging, peripheral arterial tonometry, optical coherence tomography and nailfold video-capillaroscopy, have been increasingly used to assess peripheral microvascular function and have demonstrated a number of advantages. In this review, we present functional methods to evaluate peripheral microvascular and endothelial function, and we discuss the existing evidence on circulatory dysfunction in patients with liver cirrhosis.

Keywords Cirrhosis, endothelial dysfunction, microcirculation, flow-mediated dilatation, venous occlusion plethysmography

Introduction
The endothelium is a single layer of cells lining the interior surface of blood and lymphatic vessels that plays a major role in the regulation of vascular function [1]. Among other things, it participates in the regulation of vasomotor tone and vascular permeability, the balance between procoagulant and anticoagulant activity, angiogenesis, leukocyte trafficking, inflammatory processes, and innate and acquired immunity [1]. Any impairment of endothelium, caused by physical or chemical stimuli, can lead to endothelial dysfunction, which typically includes an imbalance between vasoconstricting and vasodilating agents, procoagulant and anticoagulant factors, or growth promoting and inhibiting substances [2,3]. Nitric oxide (NO) is the vasoactive agent most commonly linked to endothelial function, since impaired NO bioavailability is the hallmark of endothelial dysfunction [4].

Liver cirrhosis is a major issue of public health, being responsible for approximately 1.2-1.3 million deaths per year worldwide, while it appears to be among the 10 most common causes of death in several countries [5-7]. The prevalence of cirrhosis is difficult to be evaluated because of the asymptomatic initial stages; thus, it was estimated at around 0.3% in surveys but at 4.5-9.5% in autopsy studies in the general adult population [6,8,9]. The most common causes of cirrhosis are chronic hepatitis B, chronic hepatitis C, alcohol-associated liver disease and non-alcoholic fatty liver disease [6]. From a circulatory standpoint, liver cirrhosis is
characterized by significant dysregulation, related to imbalance of several vasodilating agents, including NO [10]. According to current knowledge, reduced NO bioavailability and oxidative stress in the intrahepatic vascular system results in increased intrahepatic resistance and portal hypertension [11]. On the other hand, several systemic vascular beds were shown to overproduce NO, a fact linked to arterial vasodilatation and a hyperdynamic state [11]. In contrast to portal vein and macrovascular hemodynamic alterations, which have been rather well described, the peripheral microcirculatory structure and function in cirrhosis are less well studied [12,13].

As micrcirculatory endothelial dysfunction is associated with increased target organ damage, cardiovascular events and mortality in the general and other populations, there is a need for a better description of the status and the impact of peripheral endothelial dysfunction in cirrhosis [13-17].

During the last decades, a number of methods have been used to assess endothelial and microvascular function in human studies [18]. Venous occlusion plethysmography (VOP) was used for many years as the gold standard for evaluating endothelial function, while, flow-mediated dilatation (FMD) of the forearm is currently the most frequently used method [18]. Recently, several noninvasive and easily applicable methods, such as near-infrared spectroscopy (NIRS), peripheral arterial tonometry (PAT), optical coherence tomography (OCT), and nailfold video-capillaroscopy, have gained more and more ground [18,19]. In this article, we aim to present the currently used functional methods to evaluate peripheral microvascular and endothelial function and discuss the existing evidence on circulatory dysfunction in patients with liver cirrhosis. For this purpose, we conducted a literature search in PubMed, Scopus and Web of Science databases up to 12 March 2021, using the following keywords: “cirrhosis”, “endothelial function”, “endothelial dysfunction”, “venous occlusion plethysmography”, “flow mediated dilatation”, “near infrared spectroscopy”, “capillaroscopy”, “peripheral arterial tonometry”, “glycocalyx”, “laser doppler flowmetry”, “laser speckle contrast imaging”, “laser speckle contrast analysis”, “optical coherence tomography”.

Functional methods of endothelial dysfunction assessment in cirrhosis

VOP

VOP was the first method applied for the evaluation of forearm microvascular function [18]. This method provides the opportunity to assess vascular responses to several vasoactive agents without affecting other organs and provoking systemic effects [20]. However, VOP is now rarely used in clinical research because of its semi-invasive and time-consuming nature (Table 1) [21,22]. This technique is based on the use of automatically calibrated mercury-in-silastic strain gauges which are applied around the limb under examination [18]. Typically, a cuff is placed proximally around the upper arm and inflated up to 40-50 mmHg for 10-sec intervals, followed by 5-sec intervals of deflation, while another cuff, placed around the wrist, is inflated up to 200 mmHg [22-24]. In this manner, the venous outflow from the forearm is occluded without affecting the arterial inflow and the changes in tissue volume are proportional to the arterial inflow rate [18,22].

Vascular function is assessed by measurement of changes in forearm blood flow (FBF, mL/min/100 mL tissue) induced by infusion of vasoconstricting or vasodilating substances (i.e., norepinephrine, acetylcholine, etc.) [22]. Endothelium-dependent vasodilatation is evaluated by infusion of endothelial agonists, such as acetylcholine and bradykinin, and endothelium-independent vasodilatation by infusion of direct smooth muscle relaxing agents (i.e., nitrates) [18,22].

In the setting of liver cirrhosis, VOP was the most commonly applied method in the first studies that aimed to assess peripheral vascular function and determine in vivo the factors that contribute to circulatory dysfunction. Early cross-sectional studies involving small numbers of subjects showed that there was no difference in vasoconstriction induced by N-monomethyl-L-arginine (L-NMMA), a selective inhibitor of NO synthase, between patients with cirrhosis and controls; hence, they concluded that overproduction of NO was not the sole cause of peripheral vasodilatation in cirrhosis [25-27]. Furthermore, in another cross-sectional study, Ryan et al demonstrated that there was significant hypo-responsiveness of the peripheral vessels to vasoconstrictor agents, such as norepinephrine and angiotensin II [28]. This impaired response was due to the enhanced release of endothelium-derived relaxing factors, including NO, as it was restored after inhibition of NO synthase [23,29]. With regard to vasoconstricting agents, Newby et al found that angiotensin II also contributed to basal peripheral vascular tone in cirrhotic patients, because decreased forearm blood flow, induced by infusion of angiotensin II, was augmented after the administration of losartan, a selective antagonist of angiotensin II type 1 receptor [26].

Concerning the different stages of cirrhosis, Campillo et al demonstrated that patients with advanced cirrhosis (Child-Pugh B and C) exhibited a greater vasoconstrictor response to L-NMMA and reduced response to noradrenaline, compared to patients with mild disease, suggesting that NO has a larger contribution to peripheral vasodilatation and hyperdynamic state in more advanced stages of cirrhosis [30]. Moreover, Helmy et al showed in a cross-sectional study of 8 pre-ascitic cirrhotic patients and 10 cirrhotic patients with refractory ascites that vascular responsiveness to angiotensin II can be different in different stages of cirrhosis, given the fact that losartan increased the forearm blood flow only in patients with refractory ascites [31]. As far as endothelin-1 (ET-1), another major vasoconstrictor agent is concerned, Helmy et al indicated that patients with Child-Pugh A cirrhosis exhibited a weaker vasoconstricting response to ET-1 compared to healthy individuals [32], while Vaughan et al, in a prospective study of 6 patients with end-stage cirrhosis, concluded that ET-1 evoked vasodilation in cirrhotic patients, in contrast to the vasoconstriction observed in controls, a response that was restored after liver transplantation [33].
With regards to vasodilatory responses, in several cross-sectional studies cirrhotic patients showed enhanced endothelium-mediated vasodilation, induced by acetylcholine and methacholine, in comparison with controls (Fig. 1) [23,34,35]. This hyper-responsiveness was not observed after the infusion of sodium nitroprusside, suggesting again that endothelial disturbances were primarily involved in excess vasodilation [23,35,36]. Interestingly, prospective randomized crossover studies showed that antibiotic treatment with norfloxacin restored the hypo-responsiveness to N-LMMA and the hyper-responsiveness to acetylcholine, and also restored the initially elevated forearm blood flow in cirrhotic patients, indicating that intestinal bacteria overgrowth and migration may contribute to these individuals’ endothelial vascular dysfunction [37,38].

**FMD**

FMD is a simple, noninvasive, established technique for evaluation of endothelial function in conduit arteries (e.g., brachial artery), currently widely used in human research [39,40]. It is based on the physiological capacity of arteries to respond by dilating to an increase in blood flow induced by mechanical or chemical stimuli [39]. The procedure involves the ultrasonographic measurement of arterial diameter at rest and after reactive hyperemia (Fig. 2) [39]. Reactive hyperemia is accomplished either after 5-min arterial occlusion with an inflated cuff (endothelium-dependent vasodilation), or after administration of a NO-donor, such as nitroglycerin (endothelium-independent vasodilation), and FMD is computed as a percentage change from baseline [11,39,41].

---

**Table 1 Main strengths and limitations of the functional methods used to evaluate endothelial function**

| Method          | Vascular bed                  | Strengths                                                                 | Limitations                                                                                           |
|-----------------|-------------------------------|---------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| VOP             | Forearm vasculature           | High reproducibility, High validity, Evaluation at rest and after local infusion of vasoactive factors | Semi-invasive, Time consuming                                                                          |
| FMD             | Conduit artery                | Simple, noninvasive, Inexpensive, Correlation with coronary endothelial function | High intra- and interobserver variability, Low reproducibility, Requirement of strict protocols and well-trained operators, Requirement of proper preparation (i.e., medication, environmental factors) |
| NIRS            | Muscle microcirculation       | Noninvasive, Inexpensive, Evaluation at rest and during exercise, Measure of tissue O₂ consumption | Adipose tissue thickness is a confounder, Myoglobin is a potential confounder                          |
| PAT             | Finger microvasculature       | Simple, noninvasive, High reproducibility, operator-independent            | High cost, Movement artifacts, Influence of environment                                                |
| LDF             | Skin microcirculation         | Simple, noninvasive, Continuous measurement of blood flow                 | Needs well-trained operator, Low reproducibility                                                       |
| Endothelial glyocalyx | Sublingual microcirculation | Tracer dilution method: Direct assessment of glyocalyx volume              | Tracer dilution method: Invasive, Time consuming                                                      |
|                 | Sublingual microcirculation   | OPS and SDF: Simple, noninvasive, Rapid, Bedside performance               | OPS and SDF: Indirect assessment of glyocalyx volume                                                  |
| Nailfold video-capillaroscopy | Nailfold microcirculation | Simple, noninvasive, Evaluation in 3 functional phases                    | Needs well-trained operator                                                                          |
| LSCI            | Skin microcirculation         | Simple, noninvasive, Continuous measurement of blood flow in real-time     | High cost, Needs well-trained operator, Movement artifacts                                             |
| OCT             | Retinal microcirculation      | Simple, noninvasive, High resolution imaging                               | Needs well-trained operator                                                                          |

VOP, venous occlusion plethysmography; FMD, flow-mediated dilatation; NIRS, near-infrared spectroscopy; PAT, peripheral arterial tonometry; LDF, laser Doppler flowmetry; OPS, orthogonal polarization spectral; SDF, sidestream dark field; LSCI, laser speckle contrast imaging; OCT, optical coherence tomography
During post-ischemic hyperemia, the change in arterial diameter depends mainly on endothelial NO synthesis and release [39,42]. It is noteworthy that FMD in the forearm is strongly correlated with coronary endothelial function, and is also considered as a reliable marker of NO bioavailability in several populations [19,43]. Despite the important advantages of this method, there are still some challenges regarding its practical application. Firstly, FMD has high intra- and interobserver variability, limiting its reproducibility [19]. As a consequence, it requires good standardization, strict protocols and well-trained, experienced operators [18,40]. Furthermore, there is a need for a proper preparation of the subjects with regard to medication, physical and environmental factors, so as to attenuate confounders that might have an effect on vascular responsiveness (Table 1) [40,44].

Table 2 presents studies that used FMD for the evaluation of peripheral endothelial function in patients with cirrhosis. The first studies to compare brachial artery FMD between patients with liver cirrhosis and controls included small numbers of patients (n<20) and suggested no difference between the group of cirrhotic patients as a whole and that of controls [45,46]. However, both in subgroup analyses of the above data, and in several studies that assessed the vascular function with FMD in different stages of cirrhosis, FMD levels were found to be significantly lower in early compared to advanced disease stages, indicating an exaggerated release of endothelial vasodilators, such as NO, with cirrhosis progression (Fig. 1) [11,41,45,47].

With regard to associations with coexisting disturbances, Sárközi et al showed that patients with cirrhosis exhibited greater FMD compared to controls, and this increased FMD was inversely correlated with neural baroreflex sensitivity; such findings suggest that overproduction of NO in cirrhosis may also be involved in the baroreflex impairment that is present in these patients [48]. Moreover, FMD was found to be higher in cirrhotic patients with ascites than in pre-ascitic patients, and was directly associated with an increased interlobar renal resistive index, a finding suggesting that cirrhotic patients with higher values of FMD have impaired renal microcirculatory function and are more prone to acute kidney injury [41]. Finally, in a cohort of 54 cirrhotic patients, FMD was shown to be a significant predictor of pulmonary edema after living donor liver transplantation, as higher pre-transplantation levels of FMD were significantly associated with a higher incidence of pulmonary edema after transplantation [49]. In a prospective case-control study, Rimbas et al studied cardiac function and endothelial function in 46 cirrhotic patients, demonstrating diastolic dysfunction in cirrhosis, but no difference in endothelial function between patients and controls; however, they did not correlate these parameters [50].

It must be noted, however, that not all studies using FMD found higher levels in cirrhotic patients compared to controls, or in more advanced stages of disease compared to early stages (Fig. 1) [51-53]. For example, Maracci et al found that FMD decreased with worsening stages of cirrhosis, indicating the presence of impaired and not increased vasodilation in patients with advanced cirrhosis [51]. A study of 156 patients with alcohol-related liver disease showed that increasing severity of portal hypertension was associated with coincidental deterioration of endothelial function and lower values of FMD [52]. Furthermore, in a recent study of 50 cirrhotic individuals and an equal number of controls, FMD was lower in patients with cirrhosis. In the same study, treatment with rifaximin resulted in improvement in FMD, suggesting that gut microbiota contribute to peripheral endothelial dysfunction in cirrhosis [53].

A number of factors may account for the conflicting results between early and more recent studies in the field. One of the most important confounders can be the vascular alterations evoked in patients with cirrhosis associated with preexisting or coexisting cardiovascular risk factors that can be present in these individuals, such as central obesity, hypertension, diabetes mellitus and others. A seminal study by Berzigotti et al studied exactly this issue by evaluating endothelial...
| Study [ref.] | Study type | Participants | Characteristics of cirrhotic patients | Results |
|-------------|------------|--------------|-------------------------------------|---------|
| Ponziani *et al*, 2019 [53] | Prospective, case-control | 50 cirrhotic patients and 50 HC | HCV or HBV: 52%  
ALC or NAFLD: 48%  
Child-Pugh A: 64%  
Child-Pugh B: 26%  
Child-Pugh C: 10%  
MHE: 40% | FMD was lower in cirrhotic patients compared to HC [6.35% (3.40-9.68) vs. 10.69% (7.78-13.24), P=0.0003].  
There was no difference in FMD between patients with MHE and patients without.  
In patients with MHE, there was a significant increase in FMD after treatment with rifaximin [9.65% [5.41-12.57] vs. 4.76% (2.45-7.89), P=0.015] |
| Rimbaş *et al*, 2018 [50] | Prospective, case-control | 46 cirrhotic patients and 46 age-sex matched HC | ALC: 52.17%  
HCV or HBV: 41.30%  
PBC: 2.18%  
Child-Pugh A: 50%  
Child-Pugh B: 35%  
Child-Pugh C: 15% | There was no difference in FMD between cirrhotic patients and controls [22±20 vs. 20±13 P=ns].  
Cirrhotic patients exhibited resting biventricular diastolic myocardial dysfunction |
| Armentano *et al*, 2018 [47] | Pilot cross-sectional study | 12 cirrhotic patients | Child-Pugh A: 33.3%  
Child-Pugh B: 33.3%  
Child-Pugh C: 33.3% | FMD was found to be higher in Child-Pugh C than Child-Pugh B and Child-Pugh A (9.87±2.36% vs. 8.52±4.72% vs. 5.18±2.44, respectively, P<0.05). |
| Sárközi *et al*, 2018 [48] | Cross-sectional | 24 cirrhotic patients  
23 sex-age matched HC  
*FMD was estimated in 21 cirrhotic patients and 15 HC | HCV: 50%  
ALC: 12.5%  
CC: 12.5% | FMD was higher in patients with cirrhosis compared to HC (9.81±3.77% vs. 5.59±1.36%, P<0.01).  
Neural baroreflex sensitivity was inversely related to FMD in cirrhosis (r=-0.49, P<0.05). |
| Berzigotti *et al*, 2013 [11] | Cross-sectional | 47 cirrhotic patients | HBV or HCV: 36.2%  
ALC: 51.1%  
NAFLD: 6.4%  
Child-Pugh A: 29.8%  
Child-Pugh B: 44.7%  
Child-Pugh C: 25.5% | 53% of patients had endothelial dysfunction (FMD <10%).  
Systemic endothelial dysfunction (low FMD) increased in parallel with CV risk (linear trend P=0.039).  
FMD increased in parallel with Child-Pugh score.  
The proportion of patients with systemic endothelial dysfunction decreased with worsening of Child-Pugh class. However, within each of the Child–Pugh classes, the proportion of systemic endothelial dysfunction increased according to the CV risk. |
| Chen *et al*, 2013 [49] | Prospective cohort | 54 cirrhotic patients | Not mentioned | Pre-transplantation values of FMD, NTD and FMD/NTD were higher in those who developed pulmonary edema after LT (P<0.01, P=0.01, P=0.02, respectively).  
Only FMD was found to be significant predictor of pulmonary edema after LT |
| Marcacci *et al*, 2013 [51] | Cross-sectional | 60 cirrhotic patients and 11 HC | Compensated cirrhosis: 66.7%  
 Decompensated cirrhosis: 33.3% | FMD was reduced in worsening of cirrhosis (HC: 9.9±1.1%, compensated: 6.1±1.8%, decompensated: 5±1.3%, P<0.01).  
A statistically significant correlation was observed between FMD and ET-1 (r=-0.4427), P-selectin (r=-0.477), vWF (r=-0.166). |

(Contd...)
function by FMD in cirrhosis and simultaneously taking into account the cardiovascular risk of their patients, estimated using standard risk calculators [11]. The authors observed that, while FMD increased with the deterioration of liver disease, FMD decreased and the proportion of patients with endothelial dysfunction increased with greater cardiovascular risk. Within each Child-Pugh class, the proportion of patients with endothelial dysfunction increased in parallel with the cardiovascular risk. Although these preliminary findings need to be confirmed by future studies, the authors concluded that liver failure is a confounding factor in the relation between endothelial function measured with FMD and cardiovascular risk, while on the other hand, FMD may not be uniformly increased in cirrhosis [11].

NIRS

NIRS is a relatively novel, non-invasive method that allows the assessment of tissue oxygenation and microvascular function in peripheral muscles and the brain [54]. It provides information on local oxygen consumption and blood flow using the near-infrared region of the electromagnetic spectrum and is based on the modified Beer-Lambert law (Fig. 3) [55]. Hemoglobin and myoglobin carry oxygen and their absorbance of near-infrared light depends on their oxygenation state [55]. Using a near-infrared light-source and an appropriate detector, the NIRS device offers an assessment of microvascular reactivity and muscle oxygenation via continuous monitoring of functional changes in oxygenated and deoxygenated hemoglobin separation [55,56]. NIRS can be used at rest, during exercise or during various vascular tests, such as post-occlusion hyperemia, to evaluate muscular blood flow, microvascular function, or the oxidative capacity or oxygen consumption of muscle [55,56]. In addition, NIRS can evaluate cerebral oxygenation status by evaluating relative changes from baseline in oxygenated, deoxygenated and total hemoglobin [57].

Due to its non-invasive nature and the ability to assess microvascular function, NIRS has recently been used to study patient populations with features of microvascular impairment, such as hypertensive and diabetic patients [56,58]. In patients with cirrhosis, however, NIRS has mostly been used to investigate cerebral oxygenation status [59-62]. Only

---

Table 2 (Continued)

| Study [ref.] | Study type | Participants | Characteristics of cirrhotic patients | Results |
|-------------|------------|--------------|--------------------------------------|---------|
| Gbaruko et al, 2012 [52] | Cross-sectional | 31 cirrhotic patients with expressed PH 63 ASH patients with signs of initial stage of PH 62 ASH patients without signs of PH | Not mentioned | Cirrhotic patients showed decreased FMD compared to other groups (LC: 5.4±0.15%, initial stage of PTE: 7.3±0.18%, no PH: 12.9±0.22%, P<0.05). 18% of cirrhotic patients exhibited paradoxical vasoconstriction response during reactive hyperemia. There was a reverse strong correlation between severity of PH and NO and a reverse moderate correlation between the severity of PH and FMD. |
| Cazzaniga et al, 2008 [41] | Cross-sectional | 32 cirrhotic patients 12 HC | Ascites: 68.8% HCV: 34.4% ALC: 34.4% | FMD was higher in ascitic patients [29.5% (10.3-50)] compared to pre-ascitic patients [17.3 (2.4-48.5)] and HC [11.6 (5.1-17.8)] (P<0.001). FMD was moderately correlated to interlobar renal resistance index in cirrhotic patients (r=0.52, P=0.002). |
| Angeloni et al, 2005 [45] | Cross-sectional | 19 cirrhotic patients and 20 sex- and age- matched HC | Child-Pugh A: 26.3% Child-Pugh B/C: 73.7% | FMD was similar in the 2 groups (cirrhosis: 9.4±9.5%, HC: 9.9±6.1%, NS). Child–Pugh A patients exhibited a FMD impairment while Child-Pugh B/C patients had normal FMD (3.6±11.6% vs. 11.4±8.2%, P<0.0001). |
| Cifkova et al, 2001 [46] | Prospective cohort | 15 cirrhotic patients and 12 HC | Ascites 26.6% ALC: 26.6% HCV: 33.3% CC: 13.3% | FMD of cirrhotic patients did not differ from that in healthy subjects (4.2±4.0% vs. 5.2±3.8%, NS). There was no significant change in FMD before and after liver transplantation (4.2±4.0% vs. 6.3±5.4%, NS). |

FMD, flow-mediated dilatation; HC, healthy controls; HCV, hepatitis C virus; HBV, hepatitis B virus; ALC, alcohol liver cirrhosis; NAFLD, non-alcoholic fatty liver disease; MHE, minimal hepatic encephalopathy; CC, cryptogenic cirrhosis; CV, cardiovascular; NTD, nitroglycerin-induced dilatation; LT, liver transplantation; ET-1, endothelin-1; vWF, von Willebrand factor; ASH, alcoholic steatohepatitis; PH, portal hypertension
a few studies have used NIRS to evaluate muscle oxygenation and microcirculation in patients with cirrhosis. Among these, preliminary cross-sectional studies suggest that skeletal muscle deoxyhemoglobin, and total hemoglobin increase during exercise, while in the recovery phase deoxyhemoglobin returns to a pre-exercise level and hemoglobin and oxyhemoglobin increase further, suggesting abnormalities in aerobic metabolism and in extraction of O2 during exercise [63,64]. In a cross-sectional study of 25 cirrhotic patients and 10 healthy controls, baseline muscle tissue oxygenation (StO2) was lower in the former [12]. After vascular occlusion, overshoot, area under recovery curve and recovery time were increased in cirrhotic subjects, demonstrating a vasodilatory state; hyperemia was more pronounced as Child-Pugh score increased. Moreover, after serial vascular occlusion, controls exhibited an ischemic adaptability: deoxygenation rates decreased and reactive parameters increased. The former changes were not seen in cirrhotic patients [12]. In contrast to the above, in another cross-sectional study, Wythe et al investigated 40 patients with cirrhosis and found no association between vasodilatory responses assessed with NIRS parameters at baseline and after vascular occlusion, with the severity of cirrhosis assessed using the Child-Pugh score [65].

**Laser Doppler flowmetry (LDF)**

LDF is a valid test that allows the evaluation of skin microvascular function [18]. With the assumption that changes observed in the cutaneous microcirculation reflect equivalent changes in other vascular beds, LDF is used to evaluate peripheral microvascular function [18]. This technique is based on the Doppler effect; after an initial beam of coherent light contacts moving red blood cells, its direction is altered and the emerging beam is measured by the photodiode [18,66].

The change of wavelength represents the average blood cell velocity and concentration in vessels [66]. Detailed evaluation of endothelial function can be achieved by application of post-occlusion hyperemia, thermal hyperemia, and iontophoresis combined with administration of vasoactive agents and microdialysis of pharmacological factors [18]. Although LDF is a simple and valid method, its poor reproducibility and the high cost limit its use (Table 1) [67].

As of this writing, several studies have used LDF to evaluate gastric mucosal hemodynamics in cirrhosis [68-71]; however, studies assessing peripheral endothelial function in cirrhotic patients using this method are scarce. In a cross-sectional study that included 19 cirrhotic patients and 20 healthy subjects, cutaneous blood flow was lower in cirrhotic patients than controls, while reactive hyperemia caused a greater percentage increase in cutaneous flow in the former group [72]. In another cross-sectional study, skin blood flow was significantly lower in cirrhotic patients with ascites compared to those without ascites and to controls [73]. Moreover, miconazole, an inhibitor of epoxyeicosatrienoic acid (EET) synthesis, provoked a significant reduction in baseline skin flow in all participants, but this effect was more pronounced in patients with cirrhosis, indicating a potential role of EET in the excess peripheral vasodilation observed in these individuals [73].

**Laser speckle contrast imaging (LSCI)**

LSCI is another novel, non-invasive method that measures skin microvascular blood flow (Table 1) [74]. In contrast to LDF, LSCI tracks superficial microvessels in the skin and has shown better reproducibility when coupled with functional tests (i.e., reactive post-occlusion hyperemia and local thermal hyperemia) [75]. As of this writing, LSCI has been used for evaluation of endothelium-dependent vasodilation in various populations, including patients with diabetes [76-79], but to our knowledge, there no study has applied this method in cirrhosis.
Endothelial glyocalyx

Glyocalyx is a layer of proteoglycans and glycolipids that covers the endothelial lining and protects the endothelial cells from direct contact with blood cells [18,80]. Among several other functions, it has an important role in converting shear stress into shear-dependent endothelial responses, leading to NO release [18]. There are both invasive (i.e., tracer dilution technique) and non-invasive methods for the assessment of glyocalyxal function: i.e., orthogonal polarization spectral and sidestream dark field. These methods image sublingual capillaries and estimate the thickness of the glyocalyx by measuring the perfused boundary region (PBR) [18,81]. The PBR is inversely correlated with glyocalyical thickness, and higher PBR values represent thinner and impaired glyocalyx that corresponds to vascular dysfunction [82]. A few research efforts have applied sidestream dark field to image the sublingual microcirculation and describe its quantitative and semi-quantitative characteristics in cirrhosis [65,83-85].

OCT

OCT is a novel, non-invasive technique that enables assessment of chorioretinal microvascular structures [86]. In recent years, OCT has proved to be a useful tool for the assessment of microcirculation function, and retinal microvascular abnormalities have been associated with increased cardiovascular risk in various populations [86-88]. To the best of our knowledge, only one prospective pilot study used this method in cirrhosis [89]. In this study, Gifford et al demonstrated that cirrhotic patients exhibit lower values of retinal thickness, macular volume and choroidal thickness compared to controls, while these parameters did not differ from those of patients with chronic kidney disease. Moreover, the investigators demonstrated a positive correlation between retinal thinning and markers of endothelial dysfunction. Interestingly, retinal abnormalities are resolved after transplantation [89].

PAT

PAT is a non-invasive, operator-independent technique that evaluates the peripheral microvascular function regulated by NO bioavailability [18,19,90]. The procedure consists of 3 phases: baseline, occlusion, and reactive hyperemia after occlusion [90]. The main parameter generated by PAT, the reactive hyperemia index, is a marker of microvascular endothelial function but is also closely associated with coronary endothelial function [90,91] and is considered as an independent predictor of cardiovascular events [92]. Despite the important advantages, PAT has also some potential limitations, such as the influence of environmental factors (Table 1) [90].

So far, PAT has been used for assessment of vascular endothelial function in several populations [93-97], but to our knowledge there is only one cross-sectional study to date that used PAT in cirrhosis. Berzigotti et al conducted a cross-sectional study to compare FMD and PAT in cirrhosis [98] and found that PAT could overcome the limitations of FMD, and was correlated with cardiovascular risk factors, in contrast to FMD [98].

Nailfold capillaroscopy

In recent years, the use of nailfold capillaroscopy for the assessment of microcirculation has grown because of its simple and non-invasive nature [99]. This technique provides important information about different parameters of microcirculation, such as capillary density, capillary morphology and flow velocity [99,100]. A development of capillaroscopy is the method of video-capillaroscopy, which offers the advantage of functional evaluation of capillary density during different vascular phases: i.e., baseline, during reactive post-occlusion hyperemia and after venous congestion [99]. Assessment of capillary density during venous congestion is considered the most reliable method, as it detects non-perfused capillaries that can be missed with simple capillaroscopy [101].

To the best of our knowledge, there is only one longitudinal pilot study that assessed microcirculation using the video-capillaroscopy technique in patients with cirrhosis [102]. In this study, Brito-Azevedo et al demonstrated that baseline capillary density is lower in cirrhotic patients compared to controls [102]. However, the capillary density during the post-occlusive hyperemic phase and the venous congestion phase was not assessed [102]; thus, details of the structural and functional microcirculation integrity in cirrhosis need to be assessed in future studies.

Biochemical markers

Through the years, numerous serum biomarkers have been used to assess endothelial function in human studies (Supplementary Table 1) [79]. A detailed description of them is beyond the aim of this review; thus, in the following lines, we briefly discuss the most important biomarkers used to evaluate endothelial function in cirrhosis.

Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of NO synthase that is strongly associated with atherosclerosis [103]. Elevated plasma levels of ADMA have been associated with endothelial dysfunction and higher cardiovascular risk in several populations, including cirrhotic patients [104]. Moreover, ADMA plasma levels were higher in patients with decompensated cirrhosis compared to those with earlier stages of disease and healthy controls; accordingly, it was suggested that an increase in ADMA may represent a compensatory mechanism to attenuate NO overproduction [104].

Cell-adhesion molecules—i.e., vascular adhesion molecule 1 (VCAM-1), intracellular adhesion molecule 1 (ICAM-1) and endothelial selectin (E-selectin)—are considered endothelial-specific biomarkers. Substances involved in the coagulation pathway, such as von Willebrand factor (vWF), are considered related, but not specific markers of endothelial dysfunction [79].
VCAM-1 and ICAM-1 levels are higher in cirrhotic patients than in healthy subjects and increase in parallel with disease severity [105,106]; it is notable that higher ICAM-1 levels have been associated with increased mortality in this population [106]. In addition, increased concentrations of E-selectin have also been detected in cirrhotic subjects, but in contrast to VCAM-1 and ICAM-1, E-selectin levels were inversely related with disease progression [107]. Finally, with regard to coagulation pathway molecules, several studies demonstrated a positive correlation between vWF levels and cirrhosis severity, as well as a significant association with clinical events (i.e., variceal bleeding, bacterial infection) and mortality [108-111].

Endocan is a molecule associated with systemic inflammation that has been previously suggested as a strong indicator of cardiovascular disease in several populations [112]. In a previous prospective cohort study in 68 cirrhotic patients, Toshikuni et al showed that elevated endocan levels were associated with increased mortality [113]. Moreover, another prospective cohort study that included 32 patients with cirrhotic cardiomyopathy and 51 cirrhotic patients without heart disease, showed that patients with cirrhotic cardiomyopathy exhibited lower levels of serum endocan. In the total cohort population, higher levels of endocan were associated with disease severity and adverse outcomes, suggesting that endocan may be a promising predictive marker in this population [114].

Concluding remarks

Liver cirrhosis is characterized by significant circulatory dysregulation, including both intrahepatic and extrahepatic vascular beds. Endothelial dysfunction is a hallmark of intrahepatic circulation leading to portal hypertension development. Moreover, several studies have also proposed that endothelial dysfunction may be a significant contributor to the peripheral microvascular changes in patients with cirrhosis. Evidence from initial studies that assessed peripheral endothelial function in vivo with FMD suggested an enhanced vasodilatory response with cirrhosis progression [11,41,47]. However, more recently, a number of studies using FMD demonstrated that patients with cirrhosis exhibit impaired endothelium-dependent vasodilation compared with healthy controls, which deteriorates progressively with advanced stages of the disease [51-53]. The factors accounting for these conflicting results are not known; one could have hypothesized that the presence of cardiovascular risk factors (i.e., obesity, hypertension, diabetes and others) or even established cardiovascular disease may confound the associations of cirrhosis with vasodilatory responses (Fig. 4). Based on the above, there is a need for properly designed studies to delineate the above inconsistencies. To this end, it could be extremely helpful if such studies employ novel methods (e.g., NIRS, LSCI, PAT, and nailfold capillaroscopy) for the assessment of peripheral microcirculatory structure and function that have been used in other populations, but less so in patients with cirrhosis.

References

1. Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 2007;100:158-173.
2. Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. J Hepatol 2007;46:927-934.
3. van den Oever IAM, Raterman HG, Nurmohamed MT, Simsek S. Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus. Mediators Inflamm 2010;2010:792393.
4. Jourde-Chiche N, Fakhouri F, Dou L, et al. Endothelium structure and function in kidney health and disease. Nat Rev Nephrol 2019;15:87-108.
5. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol 2019;70:151-171.

6. Calver A, Harris A, Maxwell JD, Vallance P. Effect of local inhibition of nitric oxide synthesis on forearm blood flow and dorsal hand vein size in patients with alcoholic cirrhosis. Clin Sci (Lond) 1994;86:203-208.

7. Sepanlou SG, Safari S, Bisignano C, et al. GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2020;5:245-266.

8. Scaglione S, Kliethermes S, Cao G, et al. The epidemiology of cirrhosis in the United States: a population-based study. J Clin Gastroenterol 2015;49:690-696.

9. Sarin SK, Maiwall R. World Gastroenterology Organisation. Global burden of liver disease: a true burden on health sciences and economies!! Available from: https://www.worldgastroenterology.org/publications/e-wgo/e-wgo-point-of-view-articles-collection/global-burden-of-liver-disease-a-true-burden-on-health-sciences-and-economies [Accessed 21 June 2022].

10. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991;337:776-778.

11. Berzigotti A, Erice E, Gilabert R, et al. Cardiovascular risk factors and systemic endothelial function in patients with cirrhosis. Am J Gastroenterol 2013;108:75-82.

12. Thomson SJ, Cowan ML, Forton DM, et al. A study of muscle tissue oxygenation and peripheral microcirculatory dysfunction in cirrhosis using near infrared spectroscopy. Liver Int 2010;30:463-471.

13. Davies T, Wythe S, O’Beirne J, Martin D, Gilbert-Kawai E. Review article: the role of the microcirculation in liver cirrhosis. Aliment Pharmacol Ther 2017;46:825-835.

14. Katz SD, Hryniwczik H, Hriljac I, et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation 2005;111:310-314.

15. Stam F, van Guldener C, Becker A, et al. Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn study. Am Soc Nephrol 2006;17:537-545.

16. Carrero JJ, Kyriazis J, Sonmez A, et al. Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. Clin J Am Soc Nephrol 2012;7:207-215.

17. Thuwaid JA, Hamsaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000;101:948-954.

18. Lekakis J, Abraham P, Balbarini A, et al. Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation. Eur J Cardiovasc Prev Rehabil 2011;18:775-789.

19. Flammer AJ, Anderson T, Celermajer DS, et al. The assessment of endothelial function: from research into clinical practice. Circulation 2012;126:753-767.

20. Benjamin N, Calver A, Collier J, Robinson B, Vallance P, Webb D. Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension 1995;25:918-923.

21. Maruhashi T, Kihara Y, Higashi Y. Assessment of endothelium-independent vasodilatation: from methodology to clinical perspectives. J Hypertens 2018;36:1460-1467.

22. Wilkinson IB, Webb DJ. Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications. Br J Clin Pharmacol 2001;52:631-646.

23. Battaglia S, Angus P, Chin-Dusting JP. Role of the endothelium on vasoactive agents in patients with liver cirrhosis. J Gastroenterol Hepatol 2006;21:1189-1193.

24. Glemann L, Mortensen SP, Hellsten Y. Methods for the determination of skeletal muscle blood flow: development, strengths and limitations. Eur J Appl Physiol 2018;118:1081-1094.

25. Calver A, Harris A, Maxwell JD, Vallance P. Effect of local inhibition of nitric oxide synthesis on forearm blood flow and dorsal hand vein size in patients with alcoholic cirrhosis. Clin Sci (Lond) 1994;86:203-208.

26. Newby DE, Jalan R, Masumori S, Hayes PC, Boon NA, Webb DJ. Peripheral vascular tone in patients with cirrhosis: role of the renin-angiotensin and sympathetic nervous systems. Gastrovasc Res 1998;38:221-228.

27. Helmy A, Newby DE, Jalan R, Hayes PC, Webb DJ. Enhanced vasodilatation to endothelin antagonism in patients with compensated cirrhosis and the role of nitric oxide. Gut 2003;52:410-415.

28. Ryan J, Sudhir K, Jennings G, Esler M, Dudley F. Impaired reactivity of the peripheral vasculature to pressor agents in alcoholic cirrhosis. Gastroenterology 1993;105:1167-1172.

29. Helmy A, Newby DE, Jalan R, Johnston NR, Hayes PC, Webb DJ. Nitric oxide mediates the reduced vasoconstrictor response to angiotensin II in patients with preasitic cirrhosis. J Hepatol 2003;38:44-50.

30. Campillo B, Chabrier PE, Pelle G, et al. Inhibition of nitric oxide synthesis in the forearm arterial bed of patients with advanced cirrhosis. Hepatology 1995;22:1423-1429.

31. Helmy A, Jalan R, Newby DE, Hayes PC, Webb DJ. Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. Gastroenterology 2000;118:565-572.

32. Helmy A, Jalan R, Newby DE, Johnston NR, Hayes PC, Webb DJ. Altered peripheral vascular responses to exogenous and endogenous endothelin-1 in patients with well-compensated cirrhosis. Hepatology 2001;33:826-831.

33. Vaughan RB, Angus PW, Chin-Dusting JP. Evidence for altered vascular responses to exogenous endothelin-1 in patients with advanced cirrhosis with restoration of the normal vasoconstrictor response following successful liver transplantation. Gut 2003;52:1505-1510.

34. Chatila R, Ferayorni L, Gupta T, Groszmann RJ. Local arterial vasoconstriction induced by octreotide in patients with cirrhosis. Hepatology 2000;31:572-576.

35. Albillos A, Rossí I, Cacho G, et al. Enhanced endothelium-dependent vasodilation in patients with cirrhosis. Am J Physiol 1995;268:G459-G464.

36. Helmy A, Ferguson JW, Hayes PC, Newby DE, Webb DJ. Bradykinin does not contribute to peripheral vascular tone in patients with cirrhosis and ascites. J Cardiovasc Pharmacol 2006;47:556-560.

37. Rasaratnam B, Kaye D, Jennings G, Dudley F, Chin-Dusting J. The effect of selective intestinal decongestion on the hyperdynamic circulatory state in cirrhosis. A randomized trial. Ann Intern Med 2003;139:186-193.

38. Chin-Dusting JP, Rasaratnam B, Jennings GL, Dudley FJ. Effect of fluoroquinolone on the enhanced nitric oxide-induced peripheral vasodilation seen in cirrhosis. Ann Intern Med 1997;127:985-988.

39. Corretti MC, Anderson TJ, Benjamin EJ, et al. International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-265.

40. Stout M. Flow-mediated dilatation: a review of techniques and applications. Echocardiography 2009;26:832-841.

41. Carzaniga M, Salerno F, Visen tin S, Cirello I, Donarini C, Cugno M. Increased flow-mediated vasodilation in cirrhotic patients with ascites: relationship with renal resistive index: FMD in cirrhosis. Liver Int 2008;28:1396-1401.

42. Raitakari OT, Celermajer DS. Flow-mediated dilatation. Br J Clin Pharmacol 2000;50:397-404.

43. Anderson TJ, Gerhard MD, Meredith IT, et al. Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol 1995;75:71B-74B.
44. Deanfield J, Donald A, Ferri C, et al; Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction. Part I. Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. *J Hypertens* 2005;23:7-17.

45. Angeloni L, Berzigotti A, Bianchi G, Ramilli S, Magalotti D, Zoli M. 156 Systemic endothelial function evaluated by flow-mediated dilatation of brachial artery in patients with liver cirrhosis. *J Hepatol* 2005;42(Suppl):64.

46. Cičková R, Příhá J, Trunec P, et al. Blood pressure, endothelial function and circulating endothelin concentrations in liver transplant recipients. *Hypertens* 2001;19:1359-1367.

47. Armanteno RL, Arbeiter CR, Cynamon MP, Farro I, Vitirot R, Cardellino J. Flow mediated dilatation in cirrhosis: a pilot study in different stages of the disease. *Annu Int Conf IEEE Eng Med Biol Soc* 2018;2018:4564-4566.

48. Sárközi A, Cseh D, Gerlei Z, Kollai M. Reduced neural baroreflex sensitivity is related to enhanced endothelial function in patients with end-stage liver disease. *Scand J Gastroenterol* 2018;53:193-199.

49. Chen SM, Chen CL, Chai HT, et al. High flow-mediated vasodilatation predicts pulmonary edema in liver transplant patients. *Acta Cardiol Sin* 2013;29:261-270.

50. Rimbaś RC, Baldea SM, Guerra RDGA, et al. New definition criteria of myocardial dysfunction in patients with liver cirrhosis: a speckle tracking and tissue doppler imaging study. *Ultrasound Med Biol* 2018;44:562-574.

51. Marcacci M, Fiorini M, Lattanzi A, et al. 215 Is flow-mediated dilatation of cerebral vasculature [abstract]. *J Hepatol* 2013;58:593.

52. Gharuko UK, Slykva NO, Bojchuk TM, Ivashchuk OL, Plesh IA, Cherevatenko VO. Value of endothelial dysfunction in the pathogenesis of portal hypertension. *Int J Collab Res Intern Med Public Health* 2012;4:1040-1049.

53. Ponziani FR, Funaro B, Lupascu A, et al. Minimal hepatic encephalopathy is associated with increased cerebral vascular resistance. A transcranial Doppler ultrasound study. *Sci Rep* 2019;9:15373.

54. Ferrari M, Quaresima V. A brief review on the history of human functional near-infrared spectroscopy (fNIRS) development and fields of application. *Neuroimage* 2012;63:921-935.

55. Jones S, Chiesa ST, Chaturvedi N, Hughes AD. Recent developments in near-infrared spectroscopy (NIRS) for the assessment of local skeletal muscle microvascular function and capacity to utilise oxygen. *Artery Res* 2016;16:25-33.

56. Diploma K, Triantafyllou A, Koletos N, et al. Impaired muscle oxygenation and elevated exercise blood pressure in hypertensive patients: links with vascular stiffness. *Hypertension* 2017;70:444-451.

57. Anyfantti P, Triantafyllidou E, Papadopoulos S, et al. Smoking before isometric exercise amplifies myocardial stress and dysregulates baroreceptor sensitivity and cerebral oxygenation. *J Am Soc Hypertens* 2017;11:376-384.

58. Diploma K, Triantafyllou A, Grigoriadou I, et al. Impairments in microvascular function and skeletal muscle oxygenation in women with gestational diabetes mellitus: links to cardiovascular disease risk factors. *Diabetologia* 2017;60:192-201.

59. Song JG, Jeong SM, Shin WJ, et al. Laboratory variables associated with low near-infrared cerebral oxygen saturation in icteric patients before liver transplantation surgery. *Anesth Analg* 2011;112:1347-1352.

60. Jun JG, Shin WJ, Park YS, Song JG, Kim YK, Hwang GS. Factors affecting intracranial changes in regional cerebral oxygen saturation in patients undergoing liver transplantation. *Transplant Proc* 2013;45:245-250.

61. Nakanishi H, Kurosaki M, Nakanishi K, et al. Impaired brain activity in cirrhotic patients with minimal hepatic encephalopathy: Evaluation by near-infrared spectroscopy. *Hepatol Res* 2011;41:319-326.

62. Nakanishi H, Hayakawa Y, Kubota Y, et al. Impaired brain function improved by L-carnitine in patients with cirrhosis: evaluation using near-infrared spectroscopy. *Sci Rep* 2020;10:13566.

63. Bay Nielsen H, Secher NH, Clemmensen O, Ott P. Maintained cerebral and skeletal muscle oxygenation during maximal exercise in patients with liver cirrhosis. *J Hepatol* 2005;43:266-271.

64. Doi J, Shirasaki H, Haida M, Matsuzaki S. Abnormality of energy metabolism in the skeletal muscle of patients with liver cirrhosis and changes under administration of glucose and branched-chain amino acids. *Tokai J Exp Clin Med* 2004;29:191-198.

65. Wythe S, Davies TW, O’Beirne J, Martin D, Gilbert-Kawai E. Observational study of the microcirculation in patients with liver cirrhosis. *JGH Open* 2019;3:518-524.

66. Hogas SM, Voronecuu L, Serban DN, et al. Methods and potential biomarkers for the evaluation of endothelial dysfunction in chronic kidney disease: a critical approach. *J Am Soc Hypertens* 2010;4:116-127.

67. Roustit M, Cracowski JL. Assessment of endothelial and neurovascular function in human skin microcirculation. *Trends Pharmacol Sci* 2013;34:373-384.

68. Cirera I, Panés J, Bordas JM, et al. Anemia increases gastric blood flow in noncirrhotic and cirrhotic patients. *Gastrointest Endosc* 1995;42:403-407.

69. Ohta M, Hashizume M, Higashi H, et al. Portal and gastric mucosal hemodynamics in cirrhotic patients with portal-hypertensive gastropathy. *Hepatology* 1994;20:1432-1436.

70. Shigemori H, Iwao T, Ikegami M, Toyonaga A, Tanikawa K. Effects of propranolol on gastric mucosal perfusion and serum gastrin level in cirrhotic patients with portal hypertension. *Dig Dis Sci* 1994;39:2433-2438.

71. Panés J, Picque JM, Bordas JM, et al. Reduction of gastric hyperemia by glypressin and vasopressin administration in cirrhotic patients with portal hypertensive gastropathy. *Hepatology* 1994;19:55-60.

72. Seino Y, Ohki K, Nakamura T, et al. Pathophysiological characteristics of cutaneous microcirculation in patients with liver cirrhosis: relationships to cardiovascular hemodynamics and plasma neurohormonal factors. *Microvasc Res* 1993;46:206-215.

73. Sacerdoti D, Mania D, Jiang H, et al. Increased EETs participate in peripheral endothelial dysfunction of cirrhosis. *Prostaglandins Other Lipid Mediat* 2012;98:129-132.

74. Cracowski JL, Roustit M. Current methods to assess human cutaneous blood flow: an updated focus on laser-based-techniques. *Microcirculation* 2016;23:337-344.

75. Tew GA, Klonizakis M, Crank H, Briers JD, Hodges GJ. Comparison of laser speckle contrast imaging with laser Doppler for assessing microvascular function. *Microvasc Res* 2011;82:326-332.

76. de M Matheus AS, Clemente EL, de Lourdes Guimarães Rodrigues M, Torres Valença DC, Gomes MB. Assessment of microvascular function in type 1 diabetes using laser speckle contrast imaging. *J Diabetes Complications* 2013;27:55-60.

77. Borges JP, Lopes GO, Verri V, et al. A novel effective method for evaluation of endothelial dysfunction in cirrhosis. *Annals of Gastroenterology* 35
its clinical value and methods of assessment. *Curr Atheroscler Rep* 2014;16:417.

81. Nieuwopdorp M, Meuwese MC, Moolij HL, et al. Measuring endothelial glycocalyx dimensions in humans: a potential novel tool to monitor vascular vulnerability. *J Appl Physiol* (1985) 2008;104:845-852.

82. Liew H, Roberts MA, MacGinley R, McMahon LP. Endothelial glycocalyx in health and kidney disease: rising star or false dawn? *Nephrology* (Carlton) 2017;22:940-946.

83. Gonzalez Ballerga E, Pozo MO, Rubatto Birri PN, et al. Sublingual microcirculatory alterations in cirrhotic patients. *Microcirculation* 2018;25:e12448.

84. Sheikh M, Javed U, Singh J, et al. Bedside sublingual video imaging of microcirculation in assessing bacterial infection in cirrhosis. *Dig Dis Sci* 2009;54:2706-2711.

85. Reynolds T, Vivian-Smith A, Jhanji S, Pearse RM. Observational study of the effects of age, diabetes mellitus, cirrhosis and chronic kidney disease on sublingual microvascular flow. *Perioper Med (Lond)* 2013;2:7.

86. Balmforth C, van Bragt JJ, Ruijs T, et al. Chorioretinal thinning in chronic kidney disease links to inflammation and endothelial dysfunction. *JCI Insight* 2016;1:e89173.

87. Daein V, Carriere I, Kawasaki R, et al. Retinal vascular caliber is associated with cardiovascular biomarkers of oxidative stress and inflammation: the POLA study. *PLoS One* 2013;8:e71089.

88. Farrah TE, Webb DJ, Dhaun N. Retinal fingerprints for precision profiling of cardiovascular risk. *Nat Rev Cardiol* 2019;16:379-381.

89. Gifford FJ, Moroni F, Farrah TE, et al. The eye as a non-invasive window to the microcirculation in liver cirrhosis: a prospective pilot study. *J Clin Med* 2020;9:3332.

90. Hedetoft M, Olsen NV. Evaluation of endothelial function by peripheral arterial tonometry and relation with the nitric oxide pathway. *Nitrre Oxide* 2014;42:1-8.

91. Hamburg NM, Keyes MJ, Larson MG, et al. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. *Circulation* 2008;117:2467-2474.

92. Rubinstein R, Kuvin JT, Soffler M, et al. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. *Eur Heart J* 2010;31:1142-1148.

93. Hoong CWS, Tan MSL, Kao SL, Khoo EYH. Effects of external counter-pulsation on endothelial function assessed by peripheral artery tonometry, levels of glycemia and metabolic markers in individuals with type 2 diabetes mellitus. *Diabetes Metab Syndr* 2020;14:2139-2145.

94. Koo BK, Chung W-Y, Moon MK. Peripheral arterial endothelial dysfunction predicts future cardiovascular events in diabetic patients with albuminuria: a prospective cohort study. *Cardiovasc Diabetol* 2020;19:82.

95. Sang M, Fu Y, Wei C, et al. Comparison of biomarkers of endothelial dysfunction and microvascular endothelial function in patients with primary aldosteronism and essential hypertension. *J Renin Angiotensin Aldosterone Syst* 2021;22:1470320321999491.

96. Vaes AW, Spruit MA, Theunis J, Wouters EFM, De Boever P. Peripheral endothelial function is positively associated with maximal aerobic capacity in patients with chronic obstructive pulmonary disease. *Respir Med* 2018;142:41-47.

97. Theodorakopoulou MP, Bakaloudi DR, Dipla K, Zafeiridis A, Boutou AK. Vascular endothelial damage in COPD: current functional assessment methods and future perspectives. *Expert Rev Respir Med* 2021;15:1121-1133.

98. Berzigotti A, Seijo S, Reverter E, Abraldes JG, Garcia-Pagan JC, Bosch J. 590 Assessment of systemic endothelial function in patients with cirrhosis: comparison between peripheral arterial tonometry (PAT) and brachial artery vasodilatation by ultrasound (BAUS). *J Hepatol* 2011;54 Suppl:S240.

99. Schoina M, Loutradis C, Memmos E, et al. Microcirculatory function deteriorates with advancing stages of chronic kidney disease independently of arterial stiffness and atherosclerosis. *Hypertens Res* 2021;44:179-187.

100. Triantafyllou A, Anyfanti P, Pyrpasopoulou A, Triantafyllou G, Aslanidis S, Douma S. Capillary rarefaction as an index for the microvascular assessment of hypertensive patients. *Curr Hypertens Rep* 2015;17:33.

101. Serner EH, Gans RO, ter Maaten JC, Tangelder GJ, Donker AJ, Stehouwer CD. Impaired skin capillary recruitment in essential hypertension is caused by both functional and structural capillary rarefaction. *Hypertension* 2001;38:238-242.

102. Brito-Azevedo A, Perez RM, Maranhão PA, et al. Organ dysfunction in cirrhosis: a mechanism involving the microcirculation. *Eur J Gastroenterol Hepatol* 2019;31:618-625.

103. Kielerstein JT, Fliser D. The past, presence and future of ADMA in nephropathy. *Nephrol Ther* 2007;3:47-54.

104. Luch P, Segarra G, Medina P. Asymmetric dimethylarginine as a mediator of vascular dysfunction in cirrhosis. *World J Gastroenterol* 2015;21:9466-9475.

105. Pirisi M, Fabris C, Falletti E, et al. Serum soluble vascular-cell adhesion molecule-1 (VCAM-1) in patients with acute and chronic liver diseases. *Dis Markers* 1996;13:11-17.

106. Girón-González JA, Martínez-Sierra C, Rodriguez-Ramos C, et al. Adhesion molecules as a prognostic marker of liver cirrhosis. *Scand J Gastroenterol* 2005;40:217-224.

107. Cervello M, Virruso L, Lipani G, et al. Serum concentration of E-selectin in patients with chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. *J Cancer Res Clin Oncol* 2000;126:345-351.

108. La Mura V, Reverter JC, Flores-Arroyo A, et al. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. *Gut* 2011;60:1133-1138.

109. Ferlitsch M, Reiberger T, Hoke M, et al. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. *Hepatology* 2012;56:1439-1447.

110. Di Martino V, Wei D, Cervoni JP, Theyenot N. New prognostic markers in liver cirrhosis. *World J Hepatol* 2015;7:1244-1250.

111. Merli M, Di Gregorio V. Editorial: von Willebrand factor levels may predict survival in liver cirrhosis. *Aliment Pharmacol Ther* 2018;47:1536-1537.

112. Balta S, Mikhailidis DP, Demirkol S, Ozurtuk C, Celik T, Izysoy A. Endocan: A novel inflammatory indicator in cardiovascular disease? *Atherosclerosis* 2021;20:339-343.

113. Toshikuni N, Ozaki K, George J, Tsutsumi M. Serum endocan levels may predict survival in liver cirrhosis. *Hepatology* 2012;56:179-187.

114. Brito-Azevedo A, Perez RM, Maranhão PA, et al. Organ dysfunction in cirrhosis: a mechanism involving the microcirculation. *Eur J Gastroenterol Hepatol* 2019;31:618-625.

115. Kielerstein JT, Fliser D. The past, presence and future of ADMA in nephropathy. *Nephrol Ther* 2007;3:47-54.

116. Luch P, Segarra G, Medina P. Asymmetric dimethylarginine as a mediator of vascular dysfunction in cirrhosis. *World J Gastroenterol* 2015;21:9466-9475.

117. Pirisi M, Fabris C, Falletti E, et al. Serum soluble vascular-cell adhesion molecule-1 (VCAM-1) in patients with acute and chronic liver diseases. *Dis Markers* 1996;13:11-17.

118. Girón-González JA, Martínez-Sierra C, Rodriguez-Ramos C, et al. Adhesion molecules as a prognostic marker of liver cirrhosis. *Scand J Gastroenterol* 2005;40:217-224.

119. Cervello M, Virruso L, Lipani G, et al. Serum concentration of E-selectin in patients with chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. *J Cancer Res Clin Oncol* 2000;126:345-351.

120. La Mura V, Reverter JC, Flores-Arroyo A, et al. von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. *Gut* 2011;60:1133-1138.

121. Ferlitsch M, Reiberger T, Hoke M, et al. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. *Hepatology* 2012;56:1439-1447.

122. Di Martino V, Wei D, Cervoni JP, Theyenot N. New prognostic markers in liver cirrhosis. *World J Hepatol* 2015;7:1244-1250.

123. Merli M, Di Gregorio V. Editorial: von Willebrand factor levels may predict survival in liver cirrhosis. *Aliment Pharmacol Ther* 2018;47:1536-1537.

124. Balta S, Mikhailidis DP, Demirkol S, Ozurtuk C, Celik T, Izysoy A. Endocan: A novel inflammatory indicator in cardiovascular disease? *Atherosclerosis* 2021;20:339-343.
**Supplementary Table 1** Most commonly used biomarkers for assessment of endothelial function in human studies

| Category                        | Biomarkers                                                                 |
|---------------------------------|-----------------------------------------------------------------------------|
| **NOS inhibitors**              | ADMA, SDMA                                                                  |
| **Coagulation pathway molecules**| vWF, ADAMTS-13, t-PA, PAI-1, fibrinogen, thrombomodulin                     |
| **Cell adhesion molecules**     | VCAM-1, ICAM-1, E-selectin, P-selectin                                       |
| **Arterial glycocalyx**         | Syndecan-1, heparin sulfate, hyaluronan                                     |
| **Microparticles**              | EMPs, PMPs                                                                  |
| **Inflammatory markers**        | CRP, ILs, TNF-a, TLRs, CD40 ligand, PTX3, MCP-1, Ang                       |
| **Oxidative stress**            | Oxidized LDL                                                                |
| **MicroRNA**                    | MiR-126                                                                    |
| **Endocan**                     |                                                                             |
| **EPC**                         |                                                                             |

NOS, nitric oxide synthase; ADMA, asymmetric dimethylarginine; SDMA, symmetric dimethylarginine; vWF, von Willebrand factor; tPA, tissue plasminogen activator; PAI-1, plasminogen activator inhibitor 1; VCAM-1, vascular cell adhesion molecule 1; ICAM-1, intracellular adhesion molecule 1; EMPs, endothelial microparticles; PMPs, platelet microparticles; CRP, C-reactive protein; ILs, interleukins; TNF-α, tumor necrosis factor-alpha; TLRs, toll-like receptors; PTX3, pentraxin 3; MCP-1, monocyte chemoattractant protein-1; Ang, angiotensin; EPC, endothelial progenitor cell